Allergan Aesthetics has secured European regulatory approval for Boey (trenibotulinumtoxinE), a rapid-onset, short-duration neuromodulator indicated for temporary improvement of frown lines in adults. The approval marks the first commercial availability of a botulinum toxin engineered for faster onset (claimed to begin within 24–48 hours) and shorter duration (~8 weeks) compared to standard formulations.
Injectables
Allergan Aesthetics Wins EU Approval for Boey — First Rapid-Onset, Short-Duration Neuromodulator
The rapid-acting toxin enters Europe; implications for glabellar-only positioning and unit economics remain to be tested.
1-YEAR MOVE
ABBV
▲11.6%
| Ticker | Company | 1-year change |
|---|---|---|
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Boey is the first rapid-onset, short-duration toxin approved in Europe, with onset claimed within 24–48 hours.
The mechanism—a recombinant botulinum toxin E—differs from the Type A toxins (onabotulinumtoxinA, abobotulinumtoxinA, incobotulinumtoxinA) that dominate current practice. Boey's positioning as glabellar-only and its shorter duration create a distinct market niche: patients seeking rapid results for events, or those trialing toxin for the first time. European adoption will test whether the premium pricing required to offset higher manufacturing complexity and shorter revenue cycles can compete against established Type A loyalty and rebate structures (Alle, Aspire programs). U.S. approval status remains unclear.
Source: original report ↗
Frequently asked questions
What is Boey and how is it different from Botox or Dysport?
Boey is a recombinant botulinum toxin E approved in Europe for treating frown lines, unlike standard neuromodulators which use Type A toxins. It's engineered for faster onset (24–48 hours) and shorter duration (~8 weeks), making it distinct from Botox, Dysport, and Xeomin which typically take 3–7 days and last 3–4 months.
How quickly does Boey work compared to traditional Botox?
Boey begins working within 24–48 hours, whereas standard botulinum toxin formulations typically require 3–7 days for visible results. This rapid onset makes Boey attractive for patients seeking quick results before events or those trying neuromodulation for the first time.
How long does Boey last and how often would patients need retreatment?
Boey lasts approximately 8 weeks compared to the standard 3–4 months for Type A toxins, meaning patients would require retreatment roughly twice as frequently. This shorter duration creates a distinct revenue cycle that practices will need to factor into pricing and scheduling strategies.
Is Boey approved in the United States?
Boey has secured European regulatory approval, but U.S. approval status remains unclear. Practices in North America should monitor FDA developments before incorporating it into their offerings.
What areas can Boey be used on?
Boey is currently positioned as glabellar-only, meaning it is indicated solely for temporary improvement of frown lines between the eyebrows in adults. It is not approved for other facial areas like crow's feet or forehead lines.
Will Boey be more expensive than Botox or Dysport?
Premium pricing is expected to offset Boey's higher manufacturing complexity and shorter revenue cycles, though whether it can compete against established Type A loyalty programs (Alle, Aspire) and rebate structures remains to be tested in the European market.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.